4Hollopeter G,Jantzen HM,Vincent D,et al.Identification of the platelet ADP receptor targeted by antithrombotic drugs.Nature,2001,409:202-207.
5Dorsam RT,Kunapuli SP.Central role of the P2Y12 receptor in platelet activation.J Clin Invest,2004,113:340-345.
6Jakubowski JA,Winters KJ,Naganuma H,et al.A novel thienopyridine antiplatelet agent.A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile.Cardivasc Drug Rev,2007,25:357-374.
7Sugidachi A,Ogawa T,Kurihara A,et al.The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite.J Thromb Haemost,2007,5:1545-1551.
8Brandt JT,Payne CD,Wiviott SD,et al.A comparison of prasugrel and clopidogrel loading doses on platelet function:magnitude of platelet inhibition is related to active metabolite formation.Am Heart J,2007,153:66.e9-16.
9Jernberg T,Payne CD,Winters KJ,et al.Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.Eur Heart J,2006,27:1166-1173.
10Payne CD,Li YG,Small DS,et al.Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.J Cardiovasc Pharmacol,2007,50:555-562.
